Related Experiment Video
Updated: Nov 15, 2025
Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models
Published on: February 2, 2024
A single-chain antibody generation system yielding CAR-T cells with superior antitumor function
Toshiki Ochi1,2, Masaki Maruta3, Kazushi Tanimoto3
1Department of Hematology, Clinical Immunology, and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Ehime, Japan. ochi.toshiki.eg@ehime-u.ac.jp.
Abstract:
Cancer immunotherapy using T cells redirected with chimeric antigen receptor (CAR) has shown a lot of promise. We have established a single-chain antibody (scFv) generation system in which scFv library-expressing CAR-T cells can be screened appropriately based on their antitumor functions. A variable region library containing the variable and J regions of the human immunoglobulin light or heavy chain was fused with the variable region of a heavy or light chain encoded by an existing tumor-specific antibody to generate a new scFv library. Then, scFv library-expressing CAR-T cells were generated and stimulated with target cells to concentrate the antigen-specific population. Using this system, target-specific recognition of CAR-T cells appeared to be finely tuned by selecting a new variable region. Importantly, we have demonstrated that the newly optimized scFv-expressing CAR-T cells had better proliferation capacity and durable phenotypes, enabling superior reactivity against advanced tumors in vivo in comparison with the original CAR-T cells. Therefore, the optimization of an scFv is needed to maximize the in vivo antitumor functions of CAR-T cells. This system may allow us to adjust an immunological synapse formed by an scFv expressed by CAR-T cells and a target antigen, representing an ideal form of CAR-T-cell immunotherapy.
Insights
Optimizing single-chain variable fragments (scFvs) enhances chimeric antigen receptor (CAR)-T cell therapy. Engineered CAR-T cells show improved proliferation and durability for better in vivo anti-tumor activity.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Chimeric antigen receptor (CAR)-T cell therapy is a promising cancer immunotherapy approach.
- The efficacy of CAR-T cells relies on the specific recognition of tumor antigens by the CAR's single-chain variable fragment (scFv).
Purpose of the Study:
- To develop a system for generating and screening scFv libraries to optimize CAR-T cell antitumor functions.
- To improve the in vivo efficacy of CAR-T cells through scFv optimization.
Main Methods:
- Established a system for generating scFv libraries by fusing variable and J regions of human immunoglobulin chains with tumor-specific antibody variable regions.
- Generated scFv library-expressing CAR-T cells and stimulated them with target cells to enrich antigen-specific populations.
- Selected and evaluated newly optimized scFv-expressing CAR-T cells for their functional properties.
Main Results:
- Demonstrated that target-specific recognition by CAR-T cells can be finely tuned through variable region selection.
- Newly optimized scFv-expressing CAR-T cells exhibited enhanced proliferation capacity and durable phenotypes.
- These optimized CAR-T cells showed superior in vivo reactivity against advanced tumors compared to original CAR-T cells.
Conclusions:
- Optimization of scFvs is crucial for maximizing the in vivo antitumor functions of CAR-T cells.
- The developed system allows for the fine-tuning of the immunological synapse between scFv and target antigen.
- This approach represents an advanced strategy for CAR-T cell immunotherapy.
